patents
China Patent Law Update: Second Reading of Draft Amendments
By AWA | Posted on August 11, 2020
The Standing Committee of the National People’s Congress released the second reading of the draft amendments to the PRC Patent Law in July, with comments on the draft due by August 16, 2020. Compared to the previous draft amendments in 2019, the most significant change reinstates partial design protection. This was suggested in an earlier...
How to fast track patent applications in China through prioritised patent examination
By AWA | Posted on June 24, 2020
The Patent Prosecution Highway (PPH) is often used by applicants to expedite patent examinations. In China, an alternative to speed up examinations is the prioritised patent examination. Prioritised patent examination is not a new concept in China. It was first introduced in 2012 and most recently amended in 2017 in the Administrative Measures for Prioritised...
Tags: china, CNIPA, green technology, new technology, patents, PPH, Priortised Patent Examination
Fine Tuning Commercial IP Portfolios: Value, Cost Savings and Investing in the Future
By AWA | Posted on June 2, 2020
There has never been a better time to review your company’s IP portfolio than in the current business climate. This interactive webinar considers ways to fine tune the portfolio to generate cost savings, highlight the importance of IP to key decision makers, align IP and commercial interests as well as getting a jump start on...
Tags: commercial, investments, IP, patents, portfolio, strategy
Faster and Stronger Protection for New Technologies in China
By AWA | Posted on May 22, 2020
There have been a series of amendments to China’s Patent Examination Guidelines over the past year, especially regarding the examination of applications for technologies concerning the internet, AI, big data, block chain and business methods. Unclear issues have been clarified and examination standards unified. Join Xiaofan Chen from AWA Asia’s Beijing office who will discuss...
Tags: AI, big data, block chain, business methods, china, examination guidelines, Internet, patents
Valuation for Technology & IP Transactions in Good Times & Bad
By Thomas Ewing | Posted on May 22, 2020
Transactions involving new technologies and their related intangible assets have grown steadily. Restarting the world’s economic engines after the Coronavirus-induced shutdown suggests that such transactions may increase rapidly as firms seek to gain immediate value from their non-core assets. This webinar provides a context for valuation and discusses its role in commercial transactions (investment, M&A,...
Tags: IPR, licensing, patents, strategy, transactions, valuation
Intellectual Property and Domains for Start-ups and Scaleups
By Joacim Lydén, Kristian Martinsson | Posted on May 22, 2020
Explores the essentials when it comes to IP and domain names for start-ups and scaleups. An expert panel focuses on practical advice and business tools available in terms of branding and trademarks, innovations and patents as well as digital assets like domain names. Hosted by value creation specialist Cathrin Johansson with expert panellists Kristian Martinsson and...
Tags: domains, inventions, IPR, patents, scaleups, startups, trademarks
China becomes top international patent filer
By AWA | Posted on May 20, 2020
China filed 58,990 applications through WIPO’s Patent Cooperation Treaty (PCT) System last year, ending the US’s stronghold on the top position since the PCT began operations in 1978 by 1,150 applications. The numbers echo a sophisticated and coordinated effort to advance innovation and realise a high-value economy from the Chinese government. This is especially true considering in 1999,...
Tags: BOE, china, Huawei, IPR, Oppo, patents, PCT, Ping An, SPC
Clarifying the patentability of medical use inventions in China
By AWA | Posted on May 20, 2020
At the end of 2019, the new Coronavirus (2019-nCoV) emerged. It has gone on to infect millions of people worldwide and so far, claimed the lives of over a quarter of a million people. COVID-19 has disrupted the world economy like never before. At the same time, it has brought unprecedented global attention to disease...
Tags: china, CNIPA, EPO, Gilead, inventions, JPO, medical use, patents, Remdesivir
EPO rules plants and animals exclusively obtained by essentially biological processes not patentable
By AWA | Posted on May 18, 2020
It has been clear that essentially biological processes for the production of plants or animals are explicitly excluded from patentability under Article 53(b) EPC. However, patentability of products of the essentially biological processes, such as plants and animals, has been questioned and repeatedly visited by the Enlarged Board of Appeal in recent years. On 14...
Tags: animals, biological, Board of Appeal, EPO, interpretation, patents, plants
What patent protection does Gilead’s COVID-19 treatment Remdesivir have?
By Anders Heebøll-Nielsen, Michael Bech Sommer | Posted on April 30, 2020
On 29 April 2020 Gilead announced that its drug Remdesivir has a positive effect in the treatment of COVID-19 from a phase three trial of the drug. The investigation was so successful that for ethical reasons it was “unblinded” – the effect observed was so significant that retaining the group on placebo would prevent those...
Tags: applications, Coronavirus, COVID-19, Gilead, IPR protection, patents, PCT, Remdesivir
Recent contributors
Partner, European Patent Attorney
Senior Associate, Attorney at Law
Partner, Attorney at Law, Group Vice President
Partner, Attorney at Law, Business Area Manager
Senior Counsel, European Patent Attorney
